Cargando…
Safety and Efficacy of Doxorubicin, Cyclophosphamide, Bortezomib, Dexamethasone and Lenalidomide Followed by Bortezomib Consolidation as First-Line Therapy in Patients with Newly Diagnosed Multiple Myeloma
| Autores principales: | , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Atlantis Press
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8432336/ https://www.ncbi.nlm.nih.gov/pubmed/34595441 http://dx.doi.org/10.2991/chi.d.200116.001 |
| _version_ | 1783751138657435648 |
|---|---|
| author | Andersen, Kristian T. Hinge, Maja Szabo, Agoston Gyula Segel, Erik Ormstrup, Tina Holdgaard, Paw C. Pallisgaard, Niels Kerndrup, Gitte Plesner, Torben |
| author_facet | Andersen, Kristian T. Hinge, Maja Szabo, Agoston Gyula Segel, Erik Ormstrup, Tina Holdgaard, Paw C. Pallisgaard, Niels Kerndrup, Gitte Plesner, Torben |
| author_sort | Andersen, Kristian T. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8432336 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2020 |
| publisher | Atlantis Press |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-84323362021-09-29 Safety and Efficacy of Doxorubicin, Cyclophosphamide, Bortezomib, Dexamethasone and Lenalidomide Followed by Bortezomib Consolidation as First-Line Therapy in Patients with Newly Diagnosed Multiple Myeloma Andersen, Kristian T. Hinge, Maja Szabo, Agoston Gyula Segel, Erik Ormstrup, Tina Holdgaard, Paw C. Pallisgaard, Niels Kerndrup, Gitte Plesner, Torben Clin Hematol Int Correspondence Atlantis Press 2020-01-26 /pmc/articles/PMC8432336/ /pubmed/34595441 http://dx.doi.org/10.2991/chi.d.200116.001 Text en © 2020 International Academy for Clinical Hematology. Publishing services by Atlantis Press International B.V. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed under the CC BY-NC 4.0 license (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ). |
| spellingShingle | Correspondence Andersen, Kristian T. Hinge, Maja Szabo, Agoston Gyula Segel, Erik Ormstrup, Tina Holdgaard, Paw C. Pallisgaard, Niels Kerndrup, Gitte Plesner, Torben Safety and Efficacy of Doxorubicin, Cyclophosphamide, Bortezomib, Dexamethasone and Lenalidomide Followed by Bortezomib Consolidation as First-Line Therapy in Patients with Newly Diagnosed Multiple Myeloma |
| title | Safety and Efficacy of Doxorubicin, Cyclophosphamide, Bortezomib, Dexamethasone and Lenalidomide Followed by Bortezomib Consolidation as First-Line Therapy in Patients with Newly Diagnosed Multiple Myeloma |
| title_full | Safety and Efficacy of Doxorubicin, Cyclophosphamide, Bortezomib, Dexamethasone and Lenalidomide Followed by Bortezomib Consolidation as First-Line Therapy in Patients with Newly Diagnosed Multiple Myeloma |
| title_fullStr | Safety and Efficacy of Doxorubicin, Cyclophosphamide, Bortezomib, Dexamethasone and Lenalidomide Followed by Bortezomib Consolidation as First-Line Therapy in Patients with Newly Diagnosed Multiple Myeloma |
| title_full_unstemmed | Safety and Efficacy of Doxorubicin, Cyclophosphamide, Bortezomib, Dexamethasone and Lenalidomide Followed by Bortezomib Consolidation as First-Line Therapy in Patients with Newly Diagnosed Multiple Myeloma |
| title_short | Safety and Efficacy of Doxorubicin, Cyclophosphamide, Bortezomib, Dexamethasone and Lenalidomide Followed by Bortezomib Consolidation as First-Line Therapy in Patients with Newly Diagnosed Multiple Myeloma |
| title_sort | safety and efficacy of doxorubicin, cyclophosphamide, bortezomib, dexamethasone and lenalidomide followed by bortezomib consolidation as first-line therapy in patients with newly diagnosed multiple myeloma |
| topic | Correspondence |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8432336/ https://www.ncbi.nlm.nih.gov/pubmed/34595441 http://dx.doi.org/10.2991/chi.d.200116.001 |
| work_keys_str_mv | AT andersenkristiant safetyandefficacyofdoxorubicincyclophosphamidebortezomibdexamethasoneandlenalidomidefollowedbybortezomibconsolidationasfirstlinetherapyinpatientswithnewlydiagnosedmultiplemyeloma AT hingemaja safetyandefficacyofdoxorubicincyclophosphamidebortezomibdexamethasoneandlenalidomidefollowedbybortezomibconsolidationasfirstlinetherapyinpatientswithnewlydiagnosedmultiplemyeloma AT szaboagostongyula safetyandefficacyofdoxorubicincyclophosphamidebortezomibdexamethasoneandlenalidomidefollowedbybortezomibconsolidationasfirstlinetherapyinpatientswithnewlydiagnosedmultiplemyeloma AT segelerik safetyandefficacyofdoxorubicincyclophosphamidebortezomibdexamethasoneandlenalidomidefollowedbybortezomibconsolidationasfirstlinetherapyinpatientswithnewlydiagnosedmultiplemyeloma AT ormstruptina safetyandefficacyofdoxorubicincyclophosphamidebortezomibdexamethasoneandlenalidomidefollowedbybortezomibconsolidationasfirstlinetherapyinpatientswithnewlydiagnosedmultiplemyeloma AT holdgaardpawc safetyandefficacyofdoxorubicincyclophosphamidebortezomibdexamethasoneandlenalidomidefollowedbybortezomibconsolidationasfirstlinetherapyinpatientswithnewlydiagnosedmultiplemyeloma AT pallisgaardniels safetyandefficacyofdoxorubicincyclophosphamidebortezomibdexamethasoneandlenalidomidefollowedbybortezomibconsolidationasfirstlinetherapyinpatientswithnewlydiagnosedmultiplemyeloma AT kerndrupgitte safetyandefficacyofdoxorubicincyclophosphamidebortezomibdexamethasoneandlenalidomidefollowedbybortezomibconsolidationasfirstlinetherapyinpatientswithnewlydiagnosedmultiplemyeloma AT plesnertorben safetyandefficacyofdoxorubicincyclophosphamidebortezomibdexamethasoneandlenalidomidefollowedbybortezomibconsolidationasfirstlinetherapyinpatientswithnewlydiagnosedmultiplemyeloma |